Pipeline Development
Novel Diagnostics & Innovative Therapeutics
Zomedica’s diagnostic pipeline aims to help veterinarians and their teams get better answers, faster via breakthrough technologies and by improving existing tests to accelerate speed to results while increasing sensitivity, specificity, performance and overall affordability.
Zomedica’s therapeutic pipeline is based on human approved drug formulations or compounded formulations that veterinarians already use to treat their patients. Zomedica’s therapeutic candidates are being formulated for animal physiology, tested for safety and efficacy, and submitted to the FDA Center for Veterinary Medicine (FDA-CVM) for approval.
Diagnostic Pipeline
-
TRUFORMA™ //Point-of-Care Biosensor PlatformThyroid & Adrenal Disorder Immunoassays
Zomedica has partnered with Qorvo Biotechnologies, LLC to collaborate on the development of a collection of rapid veterinary diagnostic assays with the goal to deliver reference-lab performance at the point of care. TRUFORMA™, formerly ZM-024, is expected to be comprised of a table-top instrument that uses disposable assay cartridges to test a range of samples including whole blood, serum, and plasma. Joint development work initially targets five assay candidates to detect certain thyroid and adrenal disorders in dogs and cats, which currently require reference lab immunoassay testing for reliable diagnostic results. TRUFORMA™ is an investigational device, not currently available for sale and limited to investigational use only. Assays in Development: Feline Total T4, Feline TSH, Canine TSH, Canine Free T4, Canine Cortisol, Canine eACTH
Learn More
White Papers -
ZM-020 //Point-of-Care Pathogen Detection PlatformUrine & Fecal Testing
Zomedica has partnered with Seraph Biosciences, Inc. to develop their in-clinic diagnostic analyzer for use in the detection of pathogens in companion animals. The ZM-020 diagnostic platform has the potential to screen for a wide range of pathogens in companion animal feces, urine, respiratory, and dermatological samples in minutes without the need for extensive sample prep or the use of reagents. The first tests Zomedica expects for release with the ZM-020 diagnostic platform will focus on the rapid detection of fecal parasites, potential UTI-associated urine bacteria and crystals, and leptospirosis using urine samples.
White Papers -
ZM-017 //Canine Cancer Liquid Biopsy PlatformHemangiosarcoma & Osteosarcoma
Zomedica has partnered with Celsee, Inc. to develop their circulating tumor cell (CTC) “liquid biopsy” platform for use by veterinarians as a canine cancer diagnostic. ZM-017 aims to enable veterinarians to detect canine cancers in a manner that is faster, more affordable and less invasive compared to existing methods, which can be expensive and cost prohibitive for pet owners. The first assay Zomedica expects for release with ZM-017 targets hard-to-diagnose canine cancers, such as hemangiosarcoma and osteosarcoma.
Learn More
White Papers
-
Assay Development
-
ZM-020 //Point-of-Care Pathogen Detection PlatformUrine & Fecal Testing
Zomedica has partnered with Seraph Biosciences, Inc. to develop their in-clinic diagnostic analyzer for use in the detection of pathogens in companion animals. The ZM-020 diagnostic platform has the potential to screen for a wide range of pathogens in companion animal feces, urine, respiratory, and dermatological samples in minutes without the need for extensive sample prep or the use of reagents. The first tests Zomedica expects for release with the ZM-020 diagnostic platform will focus on the rapid detection of fecal parasites, potential UTI-associated urine bacteria and crystals, and leptospirosis using urine samples.
White Papers
-
-
Verification
-
TRUFORMA™ //Point-of-Care Biosensor PlatformThyroid & Adrenal Disorder Immunoassays
Zomedica has partnered with Qorvo Biotechnologies, LLC to collaborate on the development of a collection of rapid veterinary diagnostic assays with the goal to deliver reference-lab performance at the point of care. TRUFORMA™, formerly ZM-024, is expected to be comprised of a table-top instrument that uses disposable assay cartridges to test a range of samples including whole blood, serum, and plasma. Joint development work initially targets five assay candidates to detect certain thyroid and adrenal disorders in dogs and cats, which currently require reference lab immunoassay testing for reliable diagnostic results. TRUFORMA™ is an investigational device, not currently available for sale and limited to investigational use only. Assays in Development: Feline Total T4, Feline TSH, Canine TSH, Canine Free T4, Canine Cortisol, Canine eACTH
Learn More
White Papers
-
-
Validation
-
ZM-017 //Canine Cancer Liquid Biopsy PlatformHemangiosarcoma & Osteosarcoma
Zomedica has partnered with Celsee, Inc. to develop their circulating tumor cell (CTC) “liquid biopsy” platform for use by veterinarians as a canine cancer diagnostic. ZM-017 aims to enable veterinarians to detect canine cancers in a manner that is faster, more affordable and less invasive compared to existing methods, which can be expensive and cost prohibitive for pet owners. The first assay Zomedica expects for release with ZM-017 targets hard-to-diagnose canine cancers, such as hemangiosarcoma and osteosarcoma.
Learn More
White Papers
-
-
Market Launch
Therapeutics Pipeline
Review
-
Formulation
-
Pilot Studies
-
Pivotal Studies FDA-CVM Phased Review
-
Final FDA-CVM Review FDA-CVM Phased Review
-
Market Launch
Voice of the Vet™
Investor Relations
Creating a diverse portfolio of diagnostics and therapeutics in the $10B companion animal market.
NYSE American:ZOM